Colorado Senate Bill 19-227 created the Opiate Antagonist - Naloxone Bulk Purchase Fund. It allows eligible entities to purchase opiate antagonists, such as naloxone or Narcan, at low or no cost.
All eligible entities must have a current standing order in place prior to submitting an application. Click the link to request a standing order.
Eligible entities include, but are not limited to: local public health agencies, school districts, harm reduction agencies, law enforcement, and entities with publicly accessible AEDs, which include but are not limited to recreation centers, shopping centers, and workplaces.
Ineligible entities: healthcare settings and pharmacies.
The goals of the funding are to:
Reduce the financial burden of purchasing naloxone for key partners.
Promote public health and safety for Colorado citizens.
Increase access to naloxone, which is used to reverse opioid overdoses and save lives.
Naloxone ordered through the Naloxone Bulk Purchase Fund cannot be resold.
Use of expired naloxone:
A person, who acts in good faith to furnish or administer an opiate antagonist, including an expired opiate antagonist, to an individual the person believes to be suffering an opiate-related drug overdose event or to an individual who is in a position to assist the individual at risk of experiencing an opiate-related overdose event is not liable for any civil damages for acts or omissions made as a result of the act or for any act or omission made if the opiate antagonist is stolen. Colorado Revised Statute: 13-21-108.7.
The Overdose Prevention Unit verifies each organization meets eligibility requirements. The Overdose Prevention Unit is available to provide technical assistance to ensure each entity has the correct training and information to acquire, maintain, and administer opiate antagonists safety.
Contact firstname.lastname@example.org with requests for technical assistance.
2020 Opiate Antagonist Naloxone Bulk Purchase Fund Legislative Report
Review the impact of the fund and data on the number of entities and amount of naloxone received by each eligible entity through the bulk fund.